GoodRx Holdings Financials - Benzinga

GoodRx Holdings Inc

GDRXNASDAQ

Trade with Public

Trade with Public

$3.47

-0.06-1.7%

Dern. MÀJ: Aug 31, 9:47 AM

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Actionnariat Comparer Options Rapport sur les stocks

GoodRx Holdings Financials

GoodRx Holdings (GDRX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
GoodRx Holdings Raises FY2026 Sales Guidance from $765.000M-$785.000M to $790.000M-$805.000M vs $775.751M Est

GoodRx Holdings (NASDAQ:GDRX) raises FY2026 sales outlook from $765.000 million-$785.000 million to $790.000 million-$805.000 million vs $775.751 million estimate.

Benzinga Newsdesk

PRO
GoodRx Holdings Q2 Adj. EPS $0.08, Inline, Sales $200.411M Beat $193.162M Estimate

GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.08 per share which met the analyst consensus estimate. This is a 11.11 percent decrease over earnings of $0.09 per share from the same period last year.

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
GoodRx Holdings Raises FY2026 Sales Guidance from $750.000M-$780.000M to $765.000M-$785.000M vs $764.443M Est

GoodRx Holdings (NASDAQ:GDRX) raises FY2026 sales outlook from $750.000 million-$780.000 million to $765.000 million-$785.000 million vs $764.443 million estimate.

Benzinga Newsdesk

PRO
GoodRx Holdings Q1 Adj. EPS $0.07, Inline, Sales $194.006M Beat $185.137M Estimate

GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.07 per share which met the analyst consensus estimate. This is a 22.22 percent decrease over earnings of $0.09 per share from the same period last year.

Benzinga Newsdesk

PRO
GoodRx Holdings Sees FY2026 Sales $750.000M-$780.000M vs $815.142M Est

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved